very interesting new idea brought to my attention by RHPS today.

http://www.phosphagenics.com/ is the company website and

www.cohenresearch.com has an interesting report on them

with new phosphorylation techniques (inserting a phosphate group into the chemical structure to make it much more readily absorbed into the body), they aim to deliver more effectively previously hard to transmit drugs to the body - Vitamin E (already successfully launched in US), morphine (much smaller amounts needed, so fewer side effects), and others

talks with FDA started on basis of an enhanced delivery rather than enhanced drug action - much simpler process

recently gained Aus government grant of Aus$1.7 to fund Phase I and Pre-Phase II human trials of transdermal morphine delivery

a Material Evaluation Agreement signed with major US pharma to apply PSG's technology to its patented systems

forward PE of 0.54 (yes I did get the decimal point in the right place!)

shares up from about 7p to 12p over last 3 months

listed on Ausraillian Stock Market and London AIM

must be interesting to watch at least. DYOR then do it again to make sure I'm not dreaming.

check it out and ket me know what you think

cheers
SD

Up 15% today with plenty of blue on the board.

24 other buyers so far this morning - are you among them?

Also two or three sizeable sells into a rising price - is this MM's stocking up from the institutions trimming their holdings, or what?

Thought this was worthy of note.

Peter Brabeck, head of Nestle and one of the most influential
people in the food industry, was interviewed in yesterdays Financial
Times:-

"It is my conviction that the next value creation, and it will be huge,
is going to be nutritional aspects. That is what allows you to ask 40%
more for your products".

The article continued that foods with medical benefits, otherwise known
as functional foods or nutraceuticals are expected to be the big source of
growth for the next 15 to 20 years.

http://news.ft.com/cms/s/bbda33b4-8477-11d9-ad81-00000e2511c8.html - for full article - see last 3 paragraphs.

Phosphagenics recently appointed Collins Stewart as UK broker, so this should give more exposure to UK investors.

SP has ticked up to cover the spread since I bought in a couple of weeks ago. Happy to be in for the long term.

SD

Here I am again.At last they are moving onto human experiments with their morphine product,results of these trials expected end of 2005,helped by Aussie grant.Then comes drug registration,if successful.At the moment,the analgesic effect lasts 6 hours which is not to be compared with Skye Pharma's 48 hours relief from severe pain after surgery,using their novel single dose injectable formulation of morphine...DepoDur(TM),which has now reached the market.For me,SKP has more immediate potential than PSG in this field.Maybe I'm wrong.

Ethel
Interesting news about Skye Pharma which I don't follow, so new to me. I normally do not follow pharma's at all on a general rule that they have too many extrinsic risk attaching (government regulation, unforeseen side effects, loss of patent/cheap generics and massive abortive r&d costs).

The thing I like about PSG is that it's not inventing new pharmaceuticals, but reinventing the chemical delivery method of old ones - cash generation level one. Then there are all the neutraceuticals which it is a few steps ahead of the crowd on using the same chemistry - like SEO has mutliple applications for its core technology so has PSG. Interesting breadth as well as depth to its prospects.

Hope Portugal is warmer than my office!

Brr Brr

SD

Interesting results issued today - SP up .5p. Looks good for 2005 progress.

SD

Encouraging news on the Phospha E anti-cholesterol trials causing a little tick up on the SP.



RNS Number:3458K
Phosphagenics Limited
31 March 2005

31 March 2005

Phosphagenics Limited

Phospha E significantly reduces animal blood cholesterol levels

Phosphagenics Limited today announced the results of successful animal trials
showing that treatment with Phospha E (Phosphagenics' unique vitamin E product)
reduced LDL-C (bad cholesterol) concentrations in blood by up to 40%. This
level of efficacy is unique for a supplement and is similar to that seen with
cholesterol lowering drugs that used the same animal model.

This work, conducted by Monash University at the Department of Biochemistry and
Molecular Biology, is part of the work necessary to progress Phospha E from test
tube to human trials.

"The current study extends the earlier positive in vitro findings and further
demonstrates the potential of Phospha E to prevent cardiovascular disease," said
Dr Esra Ogru, vice-president research & development.

These results indicate that Phospha E has the potential to reduce elevated
cholesterol, triglyceride and LDL levels in humans. The animal model chosen for
the trials is commonly used in cardiovascular research as it mimics many of the
properties observed clinically as part of the progression of human heart
disease, and it has been used with most of the currently marketed drugs that
lower blood lipids.

In the trials, mice were placed on a high cholesterol diet for eight weeks under
controlled conditions. Either Phospha E or regular Vitamin E was administered at
comparable doses on a daily basis starting four weeks after the commencement of
the high cholesterol diet.

Bad cholesterol (LDL-C) was reduced by up to 40% after two weeks of treatment
with Phospha E supplementation. There was no significant change in good
cholesterol levels (HDL-C) in these mice. Another heart disease risk factor,
plasma triglycerides, was also reduced by 44% after four weeks.

In marked contrast to Phospha E, no changes in blood lipid concentrations were
observed in mice fed with the regular Vitamin E. This is in line with the
results from other researchers reported in academic literature.

Heart disease is one of the major killers in Western societies. A number of
factors are instrumental in causing heart disease, including elevated
cholesterol. It has been estimated that heart disease costs Australia $3.7
billion a year and in the USA $100 billion.

A commercial form of the Phospha E product is sold in the USA and Phosphagenics
is working to extend the distribution globally.

For further information, contact Dr Esra Ogru, vice-president research and
development on 61 3 9605 5900 or 0402 080 846


This information is provided by RNS
The company news service from the London Stock Exchange
END

Good results on pre-clinical trials for transdermal delivery of peptides.

PSG has developed a radical new solution to a human-life requirement that is going to be with us for ever - effective water-soluble delivery of a massive range of drugs (from heart disease treament/prevention and diabetes to osteoporosis and VitaminE added drinks) which hitherto have only been deliverable in highly inefficient large doses which flood the body, with concommitant side effects, in order for the amount that reaches the affected area needing treatment to be sufficient.

This company is a little like SEO; once the technology - phosphorylation, briefly the chemical addition of phosphate groups to existing drugs to make them water-soluble - is fully established and authorised, its applications are almost endless across a wide range of pharma- and the new buzz-word neutra-ceutical applications.

The SP has been pretty inactive and I have no idea when it might start to wake up, but sometime between 1 to 3 years I am convinced this company will start to grow exponentially. I intend to be there for the fun.

sd




RNS Number:7724N
Phosphagenics Limited
21 June 2005

Phosphagenics Limited ("Phosphagenics") (ASX code: POH; AIM code: PSG) is
pleased to announce results of a preclinical trial in which its patented drug
delivery system, TPM-01, successfully delivered the bio-active fragment (1-34)
of human Parathyroid hormone through the skin.

Parathyroid hormone is a naturally occurring polypeptide gaining widespread
recognition in the treatment of osteoporosis. Current treatment involves daily
injection with the hormone.

Dr Esra Ogru, Phosphagenics' Vice President of Research & Development said that
this new product opportunity represented a valuable addition to Phosphagenics'
product pipeline and was an important step in the development of a comprehensive
transdermal platform technology.

"Peptides are a very important class of pharmaceutical compounds - insulin and
growth hormone are two other well known examples - that currently must be
delivered by injection. We are confident that our technology will effectively
deliver numerous peptides safely and painlessly through the skin."

"We intend to continue further development of transdermal delivery of
Parathyroid hormone and begin trials on the delivery of insulin and other
peptides using our technology".

"Phosphagenics had previously demonstrated that its technology was capable of
delivering a wide range of pharmaceutical compounds, including morphine,
testosterone, oestrogen and atropine through the skin. Parathyroid hormone was
the first peptide that we had tested so we were pleased with its success."

"Clearly, our platform technology has widespread application for the safe,
painless and effective delivery of many differing pharmaceutical compounds to
patients" said Dr Ogru.


A leading expert on osteoporosis, Professor Ego Seeman, from the Austin and
Repatriation Medical Centre, University of Melbourne and medical advisor to
Phosphagenics said the Company's animal trial results represented a significant
breakthrough as this agent has been shown to partly restore the structure of the
skeleton and reduce the risk of fractures.

"Osteoporosis, or fragile bone, is a major public health threat. It is estimated
that more than 40 million people in North America, Europe, Japan and Australia
are affected. About 40 per cent of women and 20 per cent of men in these regions
will suffer a fracture related to osteoporosis in their lifetime."

"Currently, Parathyroid hormone treatment must be delivered by injection once a
day using a special injection device. There is a need for a second generation
formulation such as a patch," said Professor Seeman.

Phosphagenics has filed a new patent application to protect its latest
discovery, bringing the total number of patents in its portfolio that have been
filed or granted to 21.

For further information please contact:

Associate Professor Andrew Vizard
Telephone: +61 3 9605 5900

www.phosphagenics.com

On a sombre day for London, PSG have published their July newsletter which makes interesting reading.

sd

http://www.phosphagenics.com

Ian - why doesn't the weblink icon work?

Large sell of 500k went through to day and the SP dipped .5p. Watch out everyone when the lock-in for directors ends on 29th July.

Although one or two may sell, my guess is they will all hold tight with a product and company this good and, when that is recognised by the market, we might start to see the progress this share deserves.

This company is to drug delivery and nutraceuticals what SEO is to packaging and frogpack - IM(not so)HO, of course.

sd

Interims announced today - nothing surprising.

REVIEW AND RESULTS OF OPERATIONS

For the 6 months ended 30 June 2005, the Company returned an after tax loss of
$1,959,467 (2004: $949,461). This is the first period that the Company has
reported its profit and loss figures on a consolidated basis, following its
purchase of Vital Health Sciences Pty Ltd in December 2004. This is also the
first period that the Company has reported in accordance with Australian
equivalents to International Financial Reporting Standards.

During the period, the Company continued with and accelerated its research
programme with the following important results:

- successfully delivering parathyroid hormone through the skin
- completion of a human trial showing that Phosphagenics technology can deliver therapeutic levels of
morphine through the skin
- completion of animal trials for its patented drug APA-01 showing that it has potential to prevent
atherosclerosis, the leading cause of heart disease in the western world
- completion of animal trials showing that Phospha E (Phosphagenic's unique vitamin E product) reduced
LDL-C (bad cholesterol) concentrations in blood by up to 40%, as well as significantly reducing levels of
plasma triglycerides, another heart disease risk factor.



The Company has also signed a letter of intent to supply Swisse Vitamins Pty Ltd
with its patented vitamin E phosphate (Phospha E) for sale to the dietary
supplement market in Australia, once regulatory approvals have been obtained.

You should also read the analyst's report by BBY dated 20th June 2005.

http://www.phosphagenics.com/main/investors_shareholders.htm

Their conclusion is the company is worth NPV of Aus$0.68 (28.5p) and even without the pharmaceuticals side, their nutraceuticals alone are worth NPV of Aus$0.29 (12.1p) compared to today's mid price of 10.5p, so the pharmaceuticals are in for free.

The SP has been up and down over the last year and is currently trading below its 200dma, but seems to have reached a plateau of support at 10.5p. You need patience, with their 3 main pharma products estimated to launch in 2007, 2008 and 2009 respectively. But this really is a company worth watching and taking the time to realise value. Recommended by RHPS.

One to tuck away and forget.

sd (aka the lone wolf)

Stockdog

Brilliant write up in equity development. Reminds me when i use to be on the chp thread all by myself, nevermind

forest - what's equity development - is there a website or better a link?

http://www.equitydevelopment.co.uk/client/index.html

SD, you will have to sign in to get article free site.

hi forest - thanks

not many followers here, but I do think the applications of their basic patents are as wide for the pharma/nutra-ceuticals world as SEO is for packaging. surprised not more interest yet, but remains a good time to keep buying IMHO.

sd

chart: http://www.asx.com.au/asx/research/chartsSearchResult.jsp?asxCode=POH&TimeFrame=D6&compare=index&indices=XJO

Above Aus Stock Exchange

Below Aus discussion site
http://www.hotcopper.com.au/

Note, PSG is POH in Aus.

Phosphagenics Limited
21 October 2005




21 October 2005



The Manager
Company Announcements Office
The Australian Stock Exchange Limited


Dear Sir



re : Second Study links Phospha E to healthy cardiovascular function



ASX and AIM listed biotechnology company Phosphagenics Limited ('Phosphagenics')
today announced results of an animal study that confirms an earlier study
suggesting that its patented product Phospha E may proactively benefit
cardiovascular health. In this new animal study, Phospha E significantly reduced
LDL-C (so-called bad cholesterol), triglycerides, and plaque formation.



The study data showed that this unique form of vitamin E lowered bad cholesterol
concentrations in blood by up to 44% and triglycerides by up to 51% in mice fed
normal diets. When fed high cholesterol diets, Phospha E significantly reduced
plaque formation in the aorta by 58%. In contrast, regular vitamin E had no
significant effect on plaque formation, or cholesterol levels. These results
confirm the earlier animal study indicating that Phospha E may have the
potential to yield healthier levels of total cholesterol, triglycerides and
LDL-C in humans. The animal model chosen for the trials is commonly used in
cardiovascular research as it mimics many of the properties observed clinically
in humans.

'We are encouraged that these results support the earlier animal study. Based on
these animal studies, as well as earlier in vitro studies, we are confident in
the potential of Phospha E to support cardiovascular health in humans,' said Dr
Esra Ogru, Executive Director of Research and Development.

'We are very pleased with these results as we continue to push forward with
research into the benefits of Phospha E. Phosphagenics intends to commence
clinical trials in humans to provide further support for the product's health
benefits, including its effect on cardiovascular health,' said Dr Ogru.



Phosphagenics has a licensing agreement with Zila Nutraceuticals, Inc., USA, a
wholly owned subsidiary of Zila, Inc., for the production and distribution of
its product under the Ester E brand in the United States, Canada and Indonesia.
Ester E is currently sold widely in the United States through retail chains and
health food stores

Nice one Forest - this company will be massive one day, but it will take a lot of hard work and patiience to bring all their products to market. Until then, no point in tracking the SP - just sit tight for 2-5 years IMHO.

sd

Good news.


Phosphagenics Limited signs Development Agreement with ALZA Corporation


Biotechnology company Phosphagenics Limited ('Phosphagenics') (ASX Code: POH;
AIM Code: PSG) today announced it has entered into a development agreement with
ALZA Corporation (ALZA).


ALZA is a leading drug delivery company with a broad range of technology
platforms. Under the terms of the agreement, ALZA will fund tests to determine
the feasibility of delivering a number of compounds nominated by ALZA using
Phosphagenics' patented transdermal delivery system, TPM-01.


Dr Esra Ogru, Executive Director of Research & Development for Phosphagenics,
said, 'Phosphagenics' transdermal technology is globally-competitive and
uniquely safe and effective, and has the potential to be applied to an
extraordinarily broad range of drugs.


'Our technology has previously been tested on a number of drugs, and has
successfully delivered insulin, parathyroid hormone, fentanyl, morphine,
estradiol, testosterone and atropine across animal skin,' added Dr Ogru.


Phosphagenics' transdermal technology, TPM-01, is a non-invasive, patient-
friendly gel applied to the skin. In April this year, TPM-01 was shown to be
effective in delivering morphine into the bloodstream through human skin in a '
proof of concept' Phase I clinical trial. Phase I trials on the transdermal
delivery of insulin with TPM-01 are planned to start in the first quarter of
2006.

Anyone know anyting about ALZA? Which country is it based in? Waht's its track-record with what other related products?

Sorry, no time to DMOR today!

sd

sd
just did a quick google search, loads of info. As you i do not have the time at the moment, be back later.

Taken from another BB.

an update by CS as well........

Phosphagenics Development agreement with Alza Corporation

Phosphagenics has entered into a development agreement with Alza Corporation, a leading drug delivery company and a subsidiary of Johnson & Johnson. Under the terms of the agreement Alza will test a range of its drugs with TPM-01, Phosphagenics transdermal drug delivery platform.

Analysis
This is a very important deal for Phosphagenics, as it provides validation for its transdermal platform technology, TPM-01. As part of the development agreement Alza will fully fund testing of TPM-01 with a broad range of drugs. Any positive outcomes of the tests should lead to a full clinical development programme. We believe that this should trigger milestone payments and a future royalty stream for Phosphagenics.

Action

Phosphagenics has already demonstrated that it can deliver a broad range of drugs and chemicals across animal skin, including insulin, parathyroid hormone, fentanyl, estrodiol and testosterone. The company has also successfully delivered Morphine transdermally using TPM-01; therefore we are confident that the technology will be used successfully with some of the drugs that Alza will test. We expect that there will be further newsflow from this collaboration in 2006.

This relationship with Alza is very valuable for Phosphagenics. The company is yet to license a partner for its lead product TPM-01/Morphine and we believe that Alza could be a potential partner.

The upside therefore possible from the transdermal work currently being undertaken is significant. We eagerly await the results of Phase II data on the morphine formulation. More importantly the work relating to cholesterol lowering and the inhibition of plaque formation in arteries offers significant upside. The shares are clearly undervalued. Our price target in valuation terms remains 170 million

sd
as requested, owned by Johnson & Johnson

ALZA Corporation is the leading provider of drug delivery solutions with the world's broadest array of technology platforms, including oral, transdermal, implantable and liposomal technologies. ALZA partners with pharmaceutical and biotechnology companies to develop and manufacture pharmaceutical products that enhance healthcare for millions of patients worldwide.

Founded in 1968 by Dr. Alejandro Zaffaroni, ALZA has over 35 years of experience in scientific innovation. ALZA technology has been incorporated in 30 commercialized products marketed in more than 80 countries. More than 3,000 US and foreign patents are active or pending.



A Problem-Solving Approach
ALZA provides value to our partners in all phases of product development, from initial concept, through manufacturing and commercialization. Many of our collaborations begin in the early phases of product development, using our pharmacologic discovery process to identify optimal delivery profiles. This process pushes the boundaries of drug delivery, and yields highly attractive options for partner companies to commercialize novel therapies.



A Center for Scientific Excellence
Our expertise spans the physical sciences, biology, engineering, clinical research and pharmacology. As a Johnson & Johnson company, ALZA extends a global reach and is dedicated to developing unmatched scientific solutions to some of the world's most critical healthcare needs.



Inventing the Future
As new compounds emerge from biotechnology and genetic research, ALZA technologies continue to evolve, providing unique delivery platforms that extend the potential of important new therapies. Year after year, we deliver results that benefit healthcare and expand market opportunities for our pharmaceutical partners

forest
Interesting - thanks
sd

sd
Something in today's Daily Mail on psg, i have not read it.

Phosphagenics Limited
14 November 2005


14 November 2005


Phosphagenics Limited


Placement of Shares


Biotechnology company Phosphagenics Limited ('Phosphagenics') (ASX Code: POH;
AIM Code: PSG) advises that it is to raise A$11.25 million (Stg.4.68 million)
via a placement of approximately 46.875 million fully paid ordinary shares to
leading overseas and domestic institutions, and other sophisticated investors,
at 24 cents (10 pence) per share. The capital raising will provide funding for
Phosphagenics' core R&D program and general expenses.


It is expected that trading in the new shares on the Australian Stock Exchange
and the London Stock Exchange's Alternative Investment Market will commence on
or around 17 November 2005.


Mr Harry Rosen, President & Executive Director said that the company was very
pleased with the response from investors. 'Support from international investors
was particularly pleasing and we believe it reflects their confidence in our
ability to meet our milestone targets and deliver on our strategic plan,' he
said.


The placement in Australia was arranged by BBY Limited, Lead Manager to the
transaction, and in the UK by London-based Collins Stewart Limited.


Mr Rosen said: 'The funds raised will be used to further develop our portfolio
of pharmaceutical and nutraceutical drugs including Phosphagenics'
globally-competitive, transdermal technology which is uniquely safe and
effective and has the potential to be applied to an extraordinarily broad range
of drugs.'


About Phosphagenics Limited


Phosphagenics Limited is a pharmaceutical and nutraceutical company with a
diversified portfolio of technologies encompassing drug delivery, drug
enhancement, and active ingredients for dietary supplements, functional foods
and personal care products.


Phosphagenics is based in Melbourne, Australia. Its shares are listed on the
Australian Stock Exchange (POH) and the London Stock Exchange's Alternative
Investment Market (PSG).


For further information, please contact Mr Harry Rosen, Phosphagenics Limited on
+61 3 9605 5900

.

Something cooking here, 130,000 buy yesterday, 50k today, yet no price movement.
keep an eye or two on these, imho.

Phosphagenics Limited
18 January 2006


Phosphagenics Limited


18 January 2006


Trial Results


Phosphagenics announces successful results from a Phase Ib clinical trial of its
transdermal morphine gel

Melbourne, VIC, Australia, 18 January 2006, Phosphagenics Limited ('
Phosphagenics'), the Australian Stock Exchange (ASX:POH) and AIM (AIM:PSG)
listed pharmaceutical and nutraceutical company, today announces successful
completion of the Phase Ib clinical trial of its transdermal morphine gel,
TPM-01/Morphine. The study demonstrated that therapeutic levels of morphine in
plasma were achieved using Phosphagenics' transdermal delivery technology.
Phosphagenics now plans to seek approval for a Phase IIa study to assess the
efficacy of TPM-01/Morphine for relief of post-operative pain, which is expected
to commence in early 2006.

The Phase Ib study, conducted over a week at the Royal Adelaide Hospital, South
Australia was an 18-patient, single dose, open label, randomised study that
examined the pharmacokinetics of Phosphagenics' transdermally delivered morphine
gel. In the study, the morphine gel, administered via a single application to
the upper arm, achieved therapeutic blood morphine levels within 2 hours and
these were maintained for over 48 hours with full clearance occurring by 72
hours. These results mirrored those achieved in a Phase Ia study on TPM-01/M,
conducted to establish the tolerability and safety of the product. The TPM-01/
Morphine research is 50% funded by an R&D START grant of $1.7 million from the
Australian Government through AusIndustry.

TPM-01/Morphine was developed using the company's proprietary transdermal
penetration enhancer technology, TPM-01. TPM-01/Morphine is a non-invasive,
patient-friendly gel that delivers morphine through the skin into the
bloodstream. While oral administration of morphine produces dose spiking and
side effects including constipation, nausea, and drowsiness, Phosphagenics
believes that topical administration may eliminate many of these side effects
and offer the opportunity for sustained delivery of morphine for chronic pain
sufferers. The current longest acting morphine products provide therapeutic
blood levels for up to 24 hours, compared to over 48 achieved with TPM-01/
Morphine.

There is currently no commercially available transdermal morphine product. The
only transdermal opioid pain killer on the market is the drug fentanyl, with
sales in excess of US$ 2bn a year. Phosphagenics has recently shown that its
transdermal technology is also applicable to fentanyl, and its success in
improving the delivery of fentanyl across the skin offers opportunities for the
Company to offer fentanyl and morphine to prospective commercial partners as
part of a portfolio of transdermal pain products.

Dr Esra Ogru, Executive Director of Research and Development at Phosphagenics,
said: 'Phosphagenics is very pleased that this Phase Ib study has successfully
confirmed the previous study which demonstrated the ability of TMP-01/Morphine
formulations to deliver therapeutic levels of morphine across the skin barrier.
The company will use the data from this and previous studies to progress the
product to the next stage of clinical development in this area of unmet medical
need'.


About Phosphagenics' TPM-01 transdermal carrier technology

TPM-01 utilises existing natural transport mechanisms to carry drugs across the
skin without disrupting the surface of the skin. In contrast, competing
technologies rely either on passive diffusion across skin membranes, and improve
drug penetration with solvents, enhancers or lasers that modify the properties
of the outermost layers of the skin, or on the use of electrical or thermal
technologies to 'push' drugs through the skin.

TPM-01 has anti-inflammatory and anti-erythema properties which minimise skin
irritation, can provide sustained transdermal delivery of drugs and can deliver
both small (e.g. morphine) and large (e.g. insulin) molecules through the skin.


About Phosphagenics Limited

Phosphagenics is a pharmaceutical and nutraceutical company with a diversified
portfolio of technologies encompassing drug delivery, drug enhancement, and
active ingredients for dietary supplements, functional foods and personal care
products. It is based in Melbourne, Australia. Its shares are listed on the
Australian Stock Exchange (POH) and the London Stock Exchange's Alternative
Investment Market (PSG). Further information regarding Phosphagenics can be
found at
www.phosphagenics.com

This company is massive in the range of what its patented technology can be applied to. It will take time to get approval worldwide, but I beleive it will happen. Good response to today's announcement (started yesterday actually - obviously information can be transdermally transmitted too - lol!). No analysis available or even really doable, but certainly a multi-bagger over 2-5 years potential.

sd

This bit is best, just hope everything goes well. Held these for ages.

There is currently no commercially available transdermal morphine product. The
only transdermal opioid pain killer on the market is the drug fentanyl, with
sales in excess of US$ 2bn a year. Phosphagenics has recently shown that its
transdermal technology is also applicable to fentanyl, and its success in
improving the delivery of fentanyl across the skin offers opportunities for the
Company to offer fentanyl and morphine to prospective commercial partners as
part of a portfolio of transdermal pain products.

Just wait till their vitamin E in soluble form gets approval to attack (sic) the heart market - bigger than morphine and bigger even than insulin market - 3 immense areas of growth aprt from the nutriceuticals opportunities. remember Astra Zedneca, Welcome, etc, etc I can still remember when they were this size - just.

sd

hi stockdog, followed you over here a few weeks ago and now thinking strongly towards getting in...though the years chart doesn't look to encouraging

GN

Glob Nom, the chart stinks, I know. But at this stage of a company in a very thin market for the shares, the chart is probably not so relevant.

Having studied chemistry at university, I have an affinity with the basic process they are doing here - phophorylation. It's "making a better light bulb" whose applications are literally endless. Just take soluble Vitamin E for cardiovascular and transdermal delivery of post-operative morphine and diabetic insulin, not to mention the more fashionable nutraceuticals. These two or three products are selling in to multi-billion dollar markets with no visible competition to the improvement they will offer once fully tested and approved. Approval for a new method of delivery is much less difficult than approval for a new drug per se.

So far they have proved themselves at each stage of technological development and regulatory approval, but I am sure we may still be some years away from break out. However, I have no problem imagining that this share could be 1.15 in 5 years time. The down side seems to have been mostly shaken out since I bought in at about 13.70 over the first 6 months of last year, barring any specific bad news, like failure to gain approval at any future stage. Although I'm down 23%, it's kind of irrellevant compared to the upside that will eventually out when the market is prepared to look at these seriously.

I'm a little light in my poprtfolio weighting on this one and it's one of my targets to top up as soon as any profit trimming (or stop lossing!) on other stocks frees up some more cash.

You (I) could have got in at 10.50p at the start of the year, as oppopsed to 12.50p offer now. But it will make no real difference to the proposition and the chances are equally likely we'll never see 10.50p again anyway.

So take a dabble, or paddle, or whatever it is you do to get your toes wet. This will give you an interest to get to learn all about this share and keep you awake for the time to put in serious money when it starts to make its first major move upwards.

WDIK, DYOR

sd

cheers SD, I think I've got my shoes and socks off but the water looks a little chilly......a little encouragement (or a push) and my toes will get dipped then I may well go for a swim.

GN

I'll hold the towel for you, but you've gotta make the ultimate decision. Good luck.

sd

Annual accounts published yesterday - the most boring uninformative stuff I've read in years, although full marks for thorough transparency. Unfortunately it tells you mor about Oz accounting standards than it does about the company. One small fact I gleaned is that Nutraceuticals division fulfilled last year's AGMS's prediction of breaking even in 2005 with a small profit of about Aus$111,000 - although who knows how the allocate central costs quite.

Frustrated by no proper Chairman or CEO's report on the activities of the company in the accounts I looked on their website and found 3 very nice reports from the AGM last May - see links below:-

http://www.phosphagenics.com/main/investors_presentations.htm

and a brokers update from Nov 2005 which makes good reading, valuing the SP at Aus$0.71 or about 28p compared to today's 10p:-

http://www.phosphagenics.com/main/Analyst_Coverage.htm

This is very much on my list to buy more whilst still at this price, when I can bear to free up some cash from my other holdings. Let's hope this year's AGM has as much to say about the company's activities and achievements as last years.

sd

I saw by chance the following report of a deal with Nestle Nutrition which may account for today's meteoric 0.25p rise. Why doesn't MaM pick this up in their RNS reports? Anyway, even though the SP has turned into a snail, one day all this positive progress will bear fruit IMHO.

sd

28 April 2006
PHOSPHAGENICS & NESTLNUTRITION SIGN AGREEMENT FOR DEVELOPMENT OF PHOSPHA E
FOR FOODS AND BEVERAGES
Melbourne, Australia and Vevey, Switzerland, 28 April 2006 Phosphagenics
Limited ("Phosphagenics"), the Australian Stock Exchange (ASX : POH) and the
London Stock Exchange's Alternative Investment Market (AIM : PSG) listed
pharmaceutical and nutraceutical company, and Nestlé Nutrition, a unit of
Nestlé S.A. the world's biggest food and beverage company, today announce that
they have entered into a research agreement to develop Phosphagenics' Phospha E
® for use in Nestlé Nutrition's products. Products containing this superior
form of vitamin E have the potential to play a role in the prevention and
treatment of metabolic syndrome.
Under the terms of the agreement, Nestlé Nutrition will contribute some of the
funding towards a full dose-response preclinical study of Phospha E®, before
full scale evaluation of the product in humans. Phospha E® has been shown in
animal trials to lower blood cholesterol and triglyceride levels and to prevent
or reduce arterial plaque formation, as well as inhibiting the main
inflammatory pathways involved in metabolic syndrome.
In return, Nestlé Nutrition has obtained an option to license Phospha E® for
its use in nutritional products that target the prevention and treatment of
metabolic syndrome. Upon completion of the preclinical trials, Nestlé Nutrition
may exercise its option, upon payment of an option fee. The agreement requires
that Nestlé Nutrition launch a product within 12 months of regulatory approval
of the product and claims, and that Phosphagenics will be responsible for the
manufacture of and sale to Nestle Nutrition of Phospha E®.
Harry Rosen, Managing Director of Phosphagenics, said "Phosphagenics is
delighted to have signed this agreement with Nestlé Nutrition, which builds on
our collaborative work so far. As one of the world's largest nutrition
companies, Nestlé Nutrition is the ideal partner to exploit the potential of
Phospha E® in nutritional products".
END
About metabolic syndrome
Metabolic syndrome is a multifactorial risk factor for cardiovascular disease
and diabetes. The root causes of metabolic syndrome are overweight/obesity,
physical inactivity, and genetic factors. It is estimated that about 27% of
adults in the US have metabolic syndrome and that one in three overweight or
obese people in the US have this condition. The condition is being diagnosed
with increasing frequency.
About Phosphagenics
Phosphagenics is a pharmaceutical and nutraceutical company with a diversified
portfolio of technologies encompassing drug delivery, drug enhancement, and
active ingredients for dietary supplements, functional foods and personal care
products. It is based in Melbourne, Australia. Its shares are listed on the
Australian Stock Exchange (POH) and the London Stock Exchange's Alternative
Investment Market (PSG). Further information regarding Phosphagenics can be
found at www.phosphagenics.com.
About Nestlé Nutrition
Nestlé Nutrition is an autonomous business operation within the Nestlé group
that manages and develops the group's core nutrition business. Through
science-based nutrition products and services, Nestlé Nutrition will help
enhance the quality of people's lives by supporting health and providing care
for specific consumer groups with special nutrition needs at every stage of
life. Its product portfolio - covering infant nutrition, healthcare nutrition,
and performance nutrition - includes such trusted and well-recognised brands
as: NAN, LACTOGEN, NESLAC, NUTREN, PEPTAMEN and POWERBAR.
For further information please contact:
Australia:
Phosphagenics Limited : Harry Rosen, Managing Director
Telephone: +61 3 9605 5900
UK:
Northbank Communications: Rowan Minnion
Telephone: +44 7886 8150
r.minnion@northbankcommunications.com
END

That's what I've got!! metabolic syndrome-where can I buy some??? lol

hmmm interesting share stockdog... wonder if these will drift some more before the perfect entry point (reading the research note, they do seem to have alot of potential)

2006-05-08 07:01:34
Phosphagenics Limited - Research Update
Phosphagenics initiates Phase 2a clinical trial of its transdermal morphine
cream

Melbourne, VIC, Australia, 8 May 2006

Phosphagenics Limited ("Phosphagenics"), the Australian Stock Exchange (ASX:
POH) and the London Stock Exchange's Alternative Investment Market (AIM:PSG)
listed pharmaceutical and nutraceutical company, today announces commencement
of a Phase 2a clinical trial of its transdermal morphine cream, TPM-01/
Morphine. The Phase 2a trial, investigating the efficacy, absorption, and
metabolism of morphine administered using Phosphagenics' novel transdermal
carrier TPM-01, will be conducted at the Royal Adelaide Hospital, South
Australia. Preliminary results are expected during the third quarter of 2006.

In the trials, doses of morphine will be examined in 48 healthy male volunteers
aged between 18 and 49 years. Volunteers will be randomly assigned into a dose
group and either receive active treatment or placebo treatment in a double
blinded manner. The efficacy of Phosphagenics transdermal morphine in producing
the well recognised effects of morphine in humans, such as changes in pupil
size and decreased response to painful stimuli, will be measured.

Dr Esra Ogru, Executive Director of Research and Development at Phosphagenics,
said: "The initiation of phase 2a clinical trials of morphine with our
proprietary transdermal delivery technology is a significant milestone in the
development or our pain management product. It will also provide further
clinical proof of the efficacy of Phosphagenics' transdermal delivery
technology."

About Phosphagenics' Transdermal Morphine

Phosphagenics' transdermal morphine (TPM-01/Morphine) is a non-invasive,
patient-friendly gel or cream that delivers morphine through the skin into the
bloodstream. Previous clinical trials of TPM-01/Morphine have achieved 48 hours
of therapeutic morphine blood levels from a single dose, which compares
favourably to the longest acting morphine products available which provide only
up to 24 hours of therapeutic blood levels per dose.

Phosphagenics expects that a transdermal product capable of providing
therapeutic blood levels of morphine for 48 hours or longer would fill an unmet
clinical need for chronic pain patients (by minimising the occurrence of
"breakthrough pain") and provide cost-effective treatment solutions for hospice
patients, especially those unable to swallow oral preparations of morphine.
There is currently no commercially available transdermal morphine product.

ENDS

Notes to Editors

About Phosphagenics' Transdermal Carrier Technology

Phosphagenics patented transdermal technology is a carrier that utilises
existing natural transport mechanisms to "carry" drugs across the skin without
disrupting the surface of the skin. In contrast, alternative transdermal
technologies either: rely on passive diffusion across skin membranes improving
drug penetration with solvents, enhancers or lasers that modify the properties
of the outermost layers of the skin; or, use electrical or thermal technologies
to "push" drugs through the skin.

Both formulations of the carrier (TPM-01 and TPM-02) have anti-inflammatory and
anti-erythema properties which minimise skin irritation, can provide sustained
transdermal delivery of drugs and can deliver a range of drugs through the
skin. TPM-01 delivers small molecule drugs (e.g. morphine, fentanyl, oxycodone,
atropine, estradiol, testosterone) and TPM-02 delivers both small and large
molecule drugs (e.g. insulin, PTH, proteins).

About Phosphagenics Limited

Phosphagenics is a pharmaceutical and nutraceutical company with a diversified
portfolio of technologies encompassing drug delivery, drug enhancement, and
active ingredients for the nutraceutical industry (dietary supplements,
functional foods and personal care products).

Phosphagenics is based in Melbourne, Australia. Its shares are listed on the
Australian Stock Exchange (POH) and the London Stock Exchange's Alternative
Investment Market (PSG). An American Depository Receipts-Level 1 facility has
been established in the US with the Bank of New York (PPGNY) for the trading of
the Company's shares in the US `Over the Counter' market. Further information
regarding Phosphagenics can be found at www.phosphagenics.com.

For further information please contact:

Phosphagenics Limited:

Dr Esra Ogru, Executive Director Research & Development

Ph: +61 3 9605 5900 or 0402 080 846

Northbank Communications

Rowan Minnion

Ph: +44 (0)20 7886 8150

r.minnion@northbankcommunications.com




END

.

Mention in shares mag today. Not read it, got it from todays news paper round up.

Plays of the Week: Buy Manganese Bronze at 222.5p - Financial Objects at 46p

Updates: Buy Ascribe and Titan Europe

Something in the Pipeline: Protherics - Skyepharma - Alizyme - Plethora Solutions - Ark Therapeutics - Phosphagenics - Ardana

.

hang on, forest, I'll just get my micro-dot reader!

sd

Thats what my mrs says!! LOL not.

over 7 million traded in oz last night, up 6.5%. Take a look at chart from start of 2004 just b4 the large spike, very similar to the one we have now. (The four steps)

Reason for dot, phone rang and had to go out. easy to find psg when i got back.

Any further developments since Shares' mention to cause the welcome lift in price last week, on reasonable volume too?

Next stop Jan's 15.5p highs?

sd

23 August 2006

Phosphagenics Limited

On 22 August 2006, the Australian Stock Exchange ("ASX") published a response
by the Company to an ASX query regarding a change in the Company's share price.
Both the published query and response are set out below:

Query:

21 August 2006

Mourice Garbutt

Company Secretary

Phosphagenics Limited

By Email only

Dear Mourice

Phosphagenics Limited (the "Company")

RE: PRICE QUERY

We have noted a change in the price of the Company's securities from a low of
$0.29 on 7 August 2006 to $0.365 at the time of writing. We have also noted an
increase in the volume of trading in the securities over this period.

In light of the price change and increase in volume, please respond to each of
the following questions.

1. Is the Companyaware of any information concerning it that has not been
announced which, if known, could be an explanation for recent trading in
the securities of the Company?

2. If the answer to question 1 is yes, can an announcement be made
immediately? If not, why not and when is it expected that an announcement
will be made?

Please note, if the answer to question 1 is yes and an announcement cannot be
made immediately, you need to contact us to discuss this and you need to
consider a trading halt (see below).

3. Is there any reason to think that there may be a change in the operating
loss before abnormal items and income tax so that the figure for the half year
ended 30 June 2006 would vary materially from the previous corresponding
period. If so, please provide details as to the extent of the likely variation.

4. Is there any reason to think that the Company may record any material
abnormal or extraordinary items for the half year ended 30 June 2006? If so,
please provide details.

5. Is there any other explanation that the Company may have for the price
change and increase in volume in the securities of the Company?

6. Please confirm that the Company is in compliance with the listing rules and,
in particular, listing rule 3.1.

Your response should be sent to me by return e-mail or by facsimile on
facsimile number (03) 9614 0303. It should not be sent to the Company
Announcements Office.

Unless the information is required immediately under listing rule 3.1, a
response is requested as soon as possible and, in any event, not later than
half an hour before the start of trading (ie before 9.30 a.m. ) on Tuesday, 22
August 2006).

Under listing rule 18.7A, a copy of this query and your response will be
released to the market, so your response should be in a suitable form and
separately address each of the questions asked. If you have any queries or
concerns, please contact me immediately.

Listing rule 3.1

Listing rule 3.1 requires an entity to give ASX immediately any information
concerning it that a reasonable person would expect to have a material effect
on the price or value of the entity's securities. The exceptions to this
requirement are set out in listing rule 3.1A.

In responding to this letter you should consult listing rule 3.1 and Guidance
Note 8 - Continuous Disclosure: listing rule 3.1.

If the information requested by this letter is information required to be given
to ASX under listing rule 3.1 your obligation is to disclose the information
immediately.

Your responsibility under listing rule 3.1 is not confined to, or necessarily
satisfied by, answering the questions set out in this letter.

Trading halt

If you are unable to respond by the time requested, or if the answer to
question 1 is yes and an announcement cannot be made immediately, you should
consider a request for a trading halt in the Company's securities. As set out
in listing rule 17.1 and Guidance Note 16 - Trading Halts we may grant a
trading halt at your request. We may require the request to be in writing. We
are not required to act on your request. You must tell us each of the
following.

* The reasons for the trading halt.

* How long you want the trading halt to last.

* The event you expect to happen that will end the trading halt.

* That you are not aware of any reason why the trading halt should not be
granted.

* Any other information necessary to inform the market about the trading
halt, or that we ask for.

The trading halt cannot extend past the commencement of normal trading on the
second day after the day on which it is granted. If a trading halt is requested
and granted and you are still unable to reply to this letter before the
commencement of trading, suspension from quotation would normally be imposed by
us from the commencement of trading if not previously requested by you. The
same applies if you have requested a trading halt because you are unable to
release information to the market, and are still unable to do so before the
commencement of trading.

If you have any queries regarding any of the above, please let me know.

Yours faithfully,

Julia Kagan

Adviser, Issuers (Melbourne)



Response:

22 August 2006


Ms Julia Kagan

Adviser, Issuer (Melbourne)

Australian Stock Exchange Limited

Level 3, Stock Exchange Centre

530 Collins Street

Melbourne Vic 3000


Dear Julia

Re: Phosphagenics Limited - Price Query

In response to your letter of 21 August the Company advises the following
responses:

1. No

2. Not applicable

3. As previously disclosed to ASX in the Company's 2005 Annual Report and
various announcements to ASX since that time, Phosphagenics has accelerated its
research programme, particularly its clinical (human) studies. In line with
this acceleration, Phosphagenics anticipates that the operating loss before
abnormal items and income tax for the half year ended 30 June 2006 will vary
materially (about $1.2 million greater) from the previous corresponding period.

4. No

5. Phosphagenics suggests that the following may provide some explanation for
the price changes and increase in volume in the securities of the Company:

A) Phosphagenics is aware that an offshore financial institution has acquired a
parcel of Phosphagenics' shares last week.

B) As previously reported to ASX on 24 July 2006 the Company commenced a
pivotal Phase I clinical trial its patented transdermal insulin delivery
platform. That announcement stated that the trial was expected to be completed
by the end of July with full analysis anticipated by September 2006. The
Company has no reason to expect that the receipt of the full analysis of the
trial and any consequence announcement to the ASX will not be within the
original time frame disclosed in the 24 July 2006 announcement. The Company is
also expecting a preliminary report from the principle investigator shortly and
will subsequently release details of this report.

6. We confirm the Company is in compliance with the Listing Rules, and in
particular Listing Rule 3.1.


Yours Faithfully

Phosphagenics Limited


Per Mourice Garbutt

Company Secretary

Getting better & better

stockdog, do you know anything about the following?

Phosphagenics is aware that an offshore financial institution has acquired a
parcel of Phosphagenics' shares last week.

I can't find it.

forest - no I don't , but isn't the ASX tedious - last year's accounts were barely readable for compliance guff and almost zilch info on the company. I always thought Ozzies were practical, easy-going folk, but ASX verges on the paranoid. Anything of real interest is ont he co's website, not in any formally required reporting.

I guess if the insti bought 3% or more PSG will have to announce this under AIM rules.

Think it more likely to be a strategic stake, rather than an opportunistic bete on soon to be released news, although no evidence to support this.

Another 3.5 years to run on my holding time frame, so plenty of time for one of thie products to really hit the market (apart from their vitE products already selling well).

sd

Thanks. Should get news soon on trials.

Not this soon!

Business Strategy
Financial News
Generics
Legal Actions
Patent Issues
Agency News
Electronic Marketing
Product Marketing News
Cardiovascular
Oncology
Pain & Inflammation
Central Nervous System
Infectious Disease
Contract Research Business
Drug Approvals
Drug Discovery
Drugs In Development
eR&D
Filed For Approval
Trial Results
Regulatory Actions
Warnings
FDA Policy
Investment Banking Healthcare
Medical/Professional


TRIAL RESULTS



Phosphagenics Successfully Delivers Insulin Across the Skin in Humans



No adverse reactions reported



Key points:


* TPM-02/Insulin applied as a gel delivered insulin through the skin and into the bloodstream

* TPM-02/Insulin significantly lowered blood glucose levels

* TPM-02/Insulin did not produce any adverse reactions

* TPM-02 carrier platform has now shown the ability to deliver large molecules (e.g. proteins) through the skin in humans

MELBOURNE, Australia, Aug. 24, 2006--Phosphagenics Limited ("Phosphagenics") (AIM:PSG; ASX: POH) announced today the interim results from its Phase I transdermal insulin clinical trial, demonstrating that it had successfully delivered insulin through the skin in a way that could radically alter patient care for many diabetics around the world, especially those with Type 2.


>From one topical application of TPM-02/Insulin applied as a gel, insulin was shown to safely penetrate the human skin and then be delivered into the blood stream over a sustained period of time.


Dr William Hsu, co-investigator for this trial and clinician at the Joslin Diabetes Center of the Harvard Medical School, Boston, USA, said the trial results are evidence of the safety and tolerability of TPM-02/Insulin and demonstrate that this technology can deliver large molecules such as proteins through the skin.


"The primary objective was to confirm the safety and tolerability of TPM-02/Insulin, and this was achieved with no adverse reactions," Dr Hsu said.


"The trial also demonstrated the ability of TPM-02/Insulin to deliver insulin into the blood stream at levels high enough to produce significant effects. This is a very impressive result, given that it was administered as a single dose to healthy volunteers.


"This technology could eventually transform and expand the world's multi-billion dollar insulin market by providing a non-invasive and effective treatment for many of the world's 194 million diabetics, the majority of which are classified as Type 2," he said.


In the study, 20 healthy male volunteers, aged between 18 and 45, fasted overnight and then randomly received a single dose of TPM-02/Insulin or a placebo gel, applied directly onto the skin. Volunteers were then monitored for a period of 48 hours to assess the primary endpoint of safety.


Conducted at the Centre for Clinical Studies in Melbourne, Australia, and in accordance with ICH GCP standards and under the guidance and supervision of Professor Leon Bach, blood glucose and insulin levels, and the insulin biomarker C-peptide were all measured as secondary endpoints.


"To see TPM-02/Insulin produce a statistically significant and sustained effect on key markers, such as blood glucose concentration, insulin, and C-peptide is very encouraging and warrants significant future development," Dr Hsu said.


Dr Esra Ogru, Executive Director of Research and Development at Phosphagenics, said that this was a milestone for Phosphagenics and allows it to now move rapidly into its next stage of development with TPM-02/Insulin.


"With this success we will now start exploring ways to apply this technology to other pharmaceutical products, as well as developing other routes of administration, such as oral and inhalation," Dr Ogru said.


Phosphagenics Managing Director, Harry Rosen added: "This result supports our recent focus on developing this novel patented technology. We expect this development to enhance international interest in Phosphagenics' technology as it is a key milestone in the delivery of large molecules effectively and safely through the skin

Shares in Phosphagenics jumped 2p to 15.5p after the company unveiled potentially very exciting results from one of its trials. The group said that the interim results from its Phase I transdermal insulin clinical trial demonstrated that it had successfully delivered insulin through the skin in a way that could radically alter patient care for many diabetics around the world, especially those with Type 2. It said that from one topical application of TPM-02/Insulin applied as a gel, insulin was shown to safely penetrate the human skin and then be delivered into the blood stream over a sustained period of time

Great news - patience rewarded!

More to come, long term. A bit in the times today under the headline "smaller stock to watch"

Phosphagenics signs development deal with 'major cosmetics co'
LONDON (AFX) - Australian biotech group Phosphagenics Ltd said it has signed a development deal with what it described as a one of the world's largest cosmetics companies.

The unnamed 'major cosmetics company' will test the feasibility of using Phosphagenics' platform technologies to enhance the delivery of cosmetic compounds.

Phosphagenics has also recently signed development deals with food company Nestle Nutrition and through-the-skin drug delivery company ALZA Corp

sd
radiocast by MD on the following www.boardroomradio.com 30th aug

On the move again up .75 on 65k vol.

This could be massive.

News Releases




12 January 2007











The Manager

Company Announcements Office

The Australian Stock Exchange Limited

Dear Sir



Re: NestlNutrition enters commercial discussions with Phosphagenics





Phosphagenics Ltd (Phosphagenics) (ASX Code: POH) (AIM Code: PSG) announced today that NestlNutrition has exercised its option to finalise the existing commercial agreement to use Phospha-E for the treatment and prevention of metabolic syndrome.



Under the terms of the option agreement, both parties must consent to all public announcements, and further details will be released once Phosphagenics has received Nestle Nutritions consent.









Yours faithfully
Phosphagenics Limited



per Mourice Garbutt
Company Secretary







Contact details:



Mr Harry Rosen

Phosphagenics Ltd

Managing Director

+61 3 9605 5900 or +61 (0)421 322 757

From Self-Trade 8/1/07

Terms: PHOSPHAGENICS LIMITED ENTITLEMENT ISSUE - FOR INFORMATION ONLY
Phosphagenics Limited has announced a Share Purchase Plan whereby shareholders were being
offered the opportunity to purchase between AUD1000.20 and AUD5000.00 worth of new shares. We
have been advised by the registrars to the Company that this is only available to holders of registered
ordinary shares and not holders of Depositary Interests in CRESTtherefore on this occasion the offer is
not available.


Now why couldn't their PR company or their Company Secretary tell me that in respnse to a simple question!

another seemingly faultless step along the way - another year or two of patience required though

http://www.digitallook.com/news/rns/2074014-104201/PSG-Pre-Clinical_Trial_Results.html?ac=209058&username=lukran